

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-11. (Canceled)

Claim 12. (Currently amended) The method as claimed in Claim ~~[[11]]~~ 17, wherein the carcinoma is gynecological carcinoma.

Claim 13. (Original) The method as claimed in Claim 12, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

Claim 14. (Currently amended) The method as claimed in Claim ~~[[11]]~~ 17, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

Claim 15. (Currently amended) The method as claimed in Claim ~~[[11]]~~ 17, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

Claim 16. (Canceled)

Claim 17. (Previously Presented) A method for prognostic evaluation of a P-LAP positive carcinoma in a patient, comprising:

- (a) contacting P-LAP positive carcinoma tissues obtained from said patient with an anti-P-LAP antibody,
- (b) measuring the intensity of the specific antigen-antibody binding between P-LAP present in the carcinoma tissues and anti-P-LAP antibody, and
- (c) correlating the intensity of the specific antigen-antibody binding with a ten-year disease-free survival rate (DFS) of said patient.